Abstract
Leflunomide, an immunosuppressant with antiviral activity, was used to treat 5 children with severe BK virus-associated hemorrhagic cystitis after hematopoietic stem cell transplantation. Without severe side effects, BK viral loads in blood and urine decreased significantly after leflunomide treatment. Compared with 7 historical controls, duration of BK virus-associated hemorrhagic cystitis was significantly shorter in patients receiving leflunomide therapy (P < 0.01).
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
BK Virus*
-
Child
-
Cystitis / drug therapy*
-
Cystitis / virology
-
Female
-
Hematopoietic Stem Cell Transplantation / adverse effects
-
Hematuria / drug therapy*
-
Hematuria / virology
-
Humans
-
Immunosuppressive Agents / adverse effects
-
Immunosuppressive Agents / therapeutic use*
-
Isoxazoles / adverse effects
-
Isoxazoles / therapeutic use*
-
Leflunomide
-
Male
-
Pilot Projects
-
Polyomavirus Infections*
-
Prospective Studies
-
Tumor Virus Infections*
-
Viral Load
Substances
-
Immunosuppressive Agents
-
Isoxazoles
-
Leflunomide